Operating Cash Flow
Neurocrine Biosciences Operating Cash Flow decreased by 62.5% to $145.80M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 125.0%, from $64.80M to $145.80M. Over 4 years (FY 2021 to FY 2025), Operating Cash Flow shows an upward trend with a 32.2% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates strong operational efficiency and cash generation, while a decrease may signal operational challenges or issues with working capital management.
Detailed definition
This metric represents the total cash generated or consumed by a company's core business operations during a specific pe...
Peer comparison
Standard across all industries; peers in the medical device and diagnostics sector typically maintain high conversion ratios of net income to operating cash flow.
net_cash_from_operatingHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $103.20M | $61.80M | $4.20M | -$40.50M | $138.10M | $98.80M | $143.00M | -$125.20M | $179.60M | $212.00M | $123.50M | $130.30M | $64.60M | $158.00M | $242.50M | $64.80M | $102.00M | $227.50M | $388.40M | $145.80M |
| QoQ Change | — | -40.1% | -93.2% | <-999% | +441.0% | -28.5% | +44.7% | -187.6% | +243.5% | +18.0% | -41.7% | +5.5% | -50.4% | +144.6% | +53.5% | -73.3% | +57.4% | +123.0% | +70.7% | -62.5% |
| YoY Change | — | — | — | — | +33.8% | +59.9% | >999% | -209.1% | +30.1% | +114.6% | -13.6% | +204.1% | -64.0% | -25.5% | +96.4% | -50.3% | +57.9% | +44.0% | +60.2% | +125.0% |
Operating Cash Flow at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's operating cash flow?
- Neurocrine Biosciences (NBIX) reported operating cash flow of $145.80M in Q1 2026.
- How has Neurocrine Biosciences's operating cash flow changed year-over-year?
- Neurocrine Biosciences's operating cash flow increased by 125.0% year-over-year, from $64.80M to $145.80M.
- What is the long-term trend for Neurocrine Biosciences's operating cash flow?
- Over 4 years (2021 to 2025), Neurocrine Biosciences's operating cash flow has grown at a 32.2% compound annual growth rate (CAGR), from $256.50M to $782.70M.
- What does operating cash flow mean?
- The amount of cash a company generates from its regular business activities.